Clinical trials: Fat; Liver
Overweight, Obese
The Effect of Protein-enriched Diet on Body Composition and Appetite
Obesity is a major problem worldwide and current dietary interventions are not proving to be enough to cease the increase in levels of obesity and its detrimental side effects, such as nonalcoholic fatty liver disease (NAFLD).
- Conditions
- Overweight, Obese, Metabolic Syndrome, Non Alcoholic Fatty Liver Disease
- Trial name
- ProteinRich (NCT01634048)
- Testing
- High Protein, low calorie meal replacement
- Where
- United Kingdom
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Imperial College London
NAFLD
Comparison of the Effects of Metformin and Pioglitazone on Liver Enzymes and Ultrasound Changes in Non-Diabetic Non-Alcoholic Fatty Liver
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a spectrum of hepatic disease ranging from fat accumulation in liver to fibrosis and cirrhosis. It affects 25% of the world population on average.
- Trial name
- NCT05521633
- Testing
- Metformin and Pioglitazone
- Where
- Pakistan
- Volunteers
- 96 people
- Sponsor
- King Edward Medical University
Nonalcoholic Fatty Liver Disease
Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in affluent countries. It may progress to cirrhosis and liver cancer. At present, there is no approved drug for NAFLD.
- Trial name
- NCT00868933
- Testing
- Low glycemic index dietary intervention program, simple lifestyle advice
- Where
- China
- Volunteers
- 159 people
- Sponsor
- Chinese University of Hong Kong
Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD), Metabolic Associated-dysfunction Steatohepatitis (MASH)
Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Adults
The goal of this randomized control trial study is to compare an acceptance-based weight loss program with an occupational therapy behavioral lifestyle modification intervention in adults with metabolic associated-dysfunction…
- Trial name
- NCT06121999
- Testing
- Standard of care acceptance-based behavioral weight loss program, Occupational therapy dietary and lifestyle modifications
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Grand Valley State University
Non-Alcoholic Fatty Liver Disease
Ambulatory Liver Fat Monitoring in Patients With Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) affects 25% of the global population and causes serious complications, including cirrhosis, hepatocellular carcinoma or mortality.
- Trial name
- NCT05754385
- Testing
- Ambulatory monitoring of liver fat, Standard of care
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The University of Hong Kong
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
NASH-FITTER: Nonalcoholic Steatohepatitis Fitness Intervention Treatment Targeting Endothelial Dysfunction Reversal
This research is being done to find out if aerobic exercise is beneficial in reversing scarring. Physical activity has been shown to increase fitness in healthy individuals as well as in those with NASH.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis
- Trial name
- NASH-FITTER (NCT03864835)
- Testing
- Moderate intensity aerobic exercise
- Sponsor
- Milton S. Hershey Medical Center
Non-alcoholic Steatohepatitis (NASH)
A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects
This is a first-in-human (FIH) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of AZD4076 tetracosasodium in healthy male subjects at increasing single doses
- Trial name
- NCT02612662
- Testing
- AZD4076
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity, Fatty Liver
Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet
To evaluate the impact of a Low Carbohydrate Ketogenic Diet (LCKD) weight loss program and compare to the standard of care program established for patients with Non-Alcoholic Fatty Liver Disease (NAFLD) on: (1) Liver fat and…
- Conditions
- Obesity, Fatty Liver, Ketogenic Dieting
- Trial name
- NCT03141008
- Testing
- Fibroscan changes with different diets
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Non-Alcoholic Fatty Liver Disease, NAFLD
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
- Conditions
- Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD
- Trial name
- SLIDE (NCT03867487)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Justin Ryder
Weight Gain
Effect of Bitter Melon Seed Oil on Body Weight
To investigate the metabolic benefits of bitter melon seed oil (BMSO), overweight or obese healthy Taiwanese adults (n=60) were randomly assigned to receive capsules containing either olive oil (OO; placebo) or BMSO at 4.5 g/d…
- Trial name
- NCT03785821
- Testing
- BMSO, OO
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- China Medical University Hospital
Non-Alcoholic Fatty Liver Disease
FCI Effectiveness in NAFLD Stratification
The goal of this pilot study is exploring whether field-cycling imaging may be able to detect characteristics of liver disease in patients with different degree of non-alcoholic fatty liver disease (NAFLD) that could be important…
- Trial name
- FIELDS (NCT05827432)
- Testing
- Field-cycling imaging (FCI)
- Where
- United Kingdom
- Sponsor
- NHS Grampian
Hepatic Steatosis
Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes
The purpose is to assess the Safety, Tolerability, and Pharmacodynamics effect of IONIS DGAT2Rx in up to 45 Adult Patients with Type 2 Diabetes.
- Trial name
- NCT03334214
- Testing
- IONIS DGAT2Rx
- Where
- 22 sites in Canada, Hungary and 2 more
- Volunteers
- 44 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
NAFLD (Nonalcoholic Fatty Liver Disease)
Evaluating the Safety and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries.
- Trial name
- NCT07900087
- Testing
- Roflumilast
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Non-Alcoholic Fatty Liver Disease
A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease.
- Trial name
- NCT03350165
- Testing
- K-877
- Where
- 16 sites in Japan
- Volunteers
- 118 people
- Sponsor
- Kowa Company, Ltd.
Nonalcoholic Fatty Liver Disease
Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores
Patients will be randomized to lifestyle changes alone or lifestyle changes associated with iron depletion. Iron depletion will be achieved by removing 350 cc of blood every 10-15 days according to baseline hemoglobin values and…
- Trial name
- NCT00658164
- Testing
- Iron depletion treatment
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Overweight and Obesity
A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight
AZD9550, previously being developed for the treatment NASH, is a dual GCG and GLP-1 receptor agonist. AZD9550 is now being developed in combination with AZD6234, a SARA, for the treatment of overweight and obesity and its…
- Trial name
- CONTEMPO (NCT06151964)
- Testing
- AZD9550, AZD9550 and AZD6234
- Where
- 15 sites in Austria, Canada and 3 more
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Overweight or Obesity and Elevated Liver Fat
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver…
- Trial name
- NCT07441252
- Testing
- Maridebart cafraglutide
- Where
- 23 sites in United States
- Volunteers
- 180 people
- Sponsor
- Amgen
Fatty Liver, Nonalcoholic, Diet, Healthy
Glycemic Index/Saturated Fatty Acid Diet and Hepatic Fat
Excessive fat in the liver is associated with impairments in metabolic health. Reducing the amount of carbohydrates and fat both have been shown to reduce liver fat.
- Conditions
- Fatty Liver, Nonalcoholic, Diet, Healthy, Obesity
- Trial name
- NCT04054297
- Testing
- High GI/SFA diet, Low GI/SFA diet
- Where
- Netherlands
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Non-alcoholic Fatty Liver Disease (NAFLD)
Assessment of Hepatic Steatosis Using Dedicated Software Implemented on Ultrasound Devices
Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease, with an estimated prevalence of 5-30% in the general population and 55-80% in patients with type 2 diabetes.
- Trial name
- NCT07268937
- Testing
- CAP (Controlled Attenuation Parameter) module implemented on the Fibroscan machine.
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Diabetes Mellitus, Non Alcholic Fatty Liver Disease
Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).
Nonalcoholic fatty liver disease (NAFLD) encompasses conditions such as nonalcoholic steatohepatitis (NASH), which involves liver inflammation and fibrosis resulting from steatosis, potentially leading to cirrhosis and…
- Trial name
- NCT07020377
- Testing
- Dapagliflozin (DAPA), Negative control
- Where
- 2 sites in Egypt
- Volunteers
- 60 people
- Sponsor
- Amira Bisher,PhD